Navigation Links
FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Aspergillosis
Date:12/3/2013

. Isavuconazole demonstrated non-inferiority versus voriconazole. Isavuconazole was effective as determined by the primary endpoint of all-cause mortality through day 42 in the intent-to-treat population (N=516). Study drug-related adverse events were reported in 42.4% of the isavuconazole and 59.8% of the voriconazole treatment group. Overall drug- and non-drug-related adverse events were reported in 96.1% and 98.5% of patients in the isavuconazole and voriconazole treatment groups, respectively.

The VITAL study is an open-label phase 3 study including patients with invasive fungal disease caused by emerging fungal pathogens such as Zygomycetes and patients with aspergillosis and pre-existing renal impairment. Enrollment into VITAL has been completed (N=150). Based on the investigator reported data, approximately 45 patients were enrolled with zygomycosis and a similar number of patients were enrolled with pre-existing renal impairment. Review of diagnosis and outcomes by an Independent Data Review Committee is ongoing.

The phase 3 ACTIVE study is a randomized, double-blind study evaluating the use of isavuconazole i.v. and oral versus caspofungin i.v. followed by oral voriconazole for the treatment of invasive Candida infections. The ACTIVE study continues to recruit with anticipated completion of enrollment in the first part of 2015.

About Astellas
Astellas Pharma US, Inc., located in Northbrook, Illinois, is a US affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma US, Inc., please visit our website at ww
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. RadSite Grants Accreditation to First Wave of MIPPA Program Applicants
2. NASDAQ Grants China Jo-Jo Drugstores 180-Day Extension to Regain Compliance with Bid Price Requirement
3. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
4. FDA Grants 510(k) Clearance for Innovative Fuse Gastroscope from EndoChoice
5. Philanthropic Grants, Product Launches, Promising Partnerships, and Customer Satisfaction Rankings - Research Report on CVS Caremark, Walgreens, McKesson, AmerisourceBergen, and Cardinal Health
6. Life Technologies Awards Digital PCR Innovation Grants to Five Research Labs
7. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
8. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
9. European Union Grants a Good Manufacturing Practice Certificate to Nelson Laboratories
10. The Kenneth Rainin Foundation Continues its Commitment to Ending Inflammatory Bowel Disease, Awarding $1.5 Million in Research Grants
11. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... support, China,s orthopedic instrument industry ... market size rising from 3.28 billion yuan in 2006 ...
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Research presented at the American College of Allergy, Asthma ... intervention to reduce over-dispensing and waste of asthma medications ... in substantial cost savings. , Medco Health Solutions, Inc. ... study that examined the effectiveness and safety of a ...
... -- New research findings presented today at ... Conference in New York show promise in assessing ... medicine (CAM) using traditional research methods. Susan Sencer, ... Clinics of Minnesota (Children,s), presented findings on the ...
Cached Medicine Technology:New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention 2New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention 3New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies 2
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... blood flow and alleviates muscle soreness after exercise, ... University of Illinois at Chicago. , The study, ... Archives of Physical Medicine and Rehabilitation , ... people who had not exercised, suggesting that massage ... of physical activity. , Improved circulation and relief ...
(Date:4/17/2014)... Johnston, whose work has transformed cancer care in Northern ... European Academy of Cancer Sciences., The Academy, which was ... highly distinguished oncologists and cancer researchers which aims to ... Europe. , Professor Johnston, whose leadership has seen cancer ... of the UK league table to near the top, ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2Health News:Massage therapy improves circulation, eases muscle soreness 2
... Amazing Contributions of John Price, an Influential ... of the YMCA for More Than 50 Years, PLEASANT HILL, ... 28th Annual Boosters Gala on Friday, October 17, 2008 at,the Diablo ... the 50 years of community service the Y has provided,throughout Contra ...
... monitored, study says , , TUESDAY, Oct. 14 (HealthDay News) ... disease may be at increased risk of developing vitamin ... essential in the body,s absorption of calcium, giving the ... strong, healthy bones. , Two separate studies, presented recently ...
... independent healthcare quality ratings company, today announced that it expects total ... approximately $10 million. This represents an increase of 23% compared with ... ... Colo. (Business Wire EON) October 14, 2008 -- HealthGrades also ...
... ... WALTHAM, Mass., Oct. 14 Decision Resources, one ... and,healthcare issues, finds that the rapid uptake of biosimilar ... drugs within this,class. The most notable near-term biosimilar targets ...
... adoption of xenograft mesh to drive revenues, according to Millennium ... ... Millennium,Research Group,s (MRG,s) US Markets for Soft Tissue Repair 2009 report, the,US ... is,expected to rise to over $825 million over the next five years. ...
... The economy is in turmoil. The,stock market appears to ... are disappearing. Headlines scream out to us and we begin ... a dream that cannot,be turned into reality. We wait to ... forthcoming. We are drowning in their silence,and a sense of ...
Cached Medicine News:Health News:Mt. Diablo Region YMCA to Celebrate 50 Years of Community Service at 28th Annual Boosters Gala on October 17, 2008 2Health News:IBD, Liver Disease Patients Show Vitamin D Deficits 2Health News: HealthGrades Expects Third Quarter Revenue of Approximately $10 Million : Full-Year 2008 Ratings and Advisory Revenue to Be $39 Million to $40 Million Company Provides Update on Stock Repurchase Program 2Health News: HealthGrades Expects Third Quarter Revenue of Approximately $10 Million : Full-Year 2008 Ratings and Advisory Revenue to Be $39 Million to $40 Million Company Provides Update on Stock Repurchase Program 3Health News:Biosimilar Monoclonal Antibodies in Oncology Will Approach Blockbuster Status by 2017 2Health News:Biosimilar Monoclonal Antibodies in Oncology Will Approach Blockbuster Status by 2017 3Health News:Ventral Hernia Repair Market to Grow to Over $800 Million in 2013 2Health News:Exercise Can Help You Cope with Financial Stress and Heal Emotional Pain, Says Acclaimed Author and Psychotherapist 2
The Fathom Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design that revolutionizes access of the most tortuous vasculature....
... (hepatitis C virus) is a Microparticle Enzyme ... anti-HCV IgG to HCV recombinant proteins in ... EDTA, sodium heparin, lithium heparin, sodium citrate ... with other laboratory results and clinical information, ...
... MasterControl architecture is the power behind ... provides all the essential building blocks ... management system to boost operational efficiency, ... with regulatory and quality standards. Click ...
... systems are automated, easy to operate and ... outside environment by flexible snap-seal pockets which ... viral contamination of the water. Offered in ... can also accommodate bags of various sizes. ...
Medicine Products: